CN117866026A

CN117866026A - Medical intermediate and preparation method thereof

Info

Publication number: CN117866026A
Application number: CN202410020968.4A
Authority: CN
Inventors: 陆阳; 陶鹏; 朱海生; 苗茹; 陆林海
Original assignee: Suzhou Novikon Biotechnology Co ltd
Current assignee: Suzhou Novikon Biotechnology Co ltd
Priority date: 2024-01-05
Filing date: 2024-01-05
Publication date: 2024-04-12

Abstract

The invention discloses a preparation method of a pharmaceutical intermediate DMT-2 '-O-propynyl-U-CE-phosphoramidite, which utilizes 5' -O-DMT-2 '-O-propynyl-uridine to obtain DMT-2' -O-propynyl-U-CE-phosphoramidite in a solvent and a phosphoramidite reagent under the action of a catalyst; wherein the phosphoramidite reagent is selected from any one of the compounds of formula I and II, and the catalyst is selected from any one of tetrazole compounds and imidazole compounds. The preparation method has simple steps, no severe requirements of special reagents and reaction conditions, less side reactions in the reaction, and high product yield and purity.

Description

Medical intermediate and preparation method thereof

Technical Field

The invention relates to the field of medicine synthesis, in particular to a medical intermediate and a preparation method thereof.

Background

Oligonucleotides have broad application prospects in cancer treatment and genetics, such as: an oligonucleotide is a short single stranded DNA or RNA, typically consisting of several to tens of nucleotides. They can bind to complementary DNA or RNA sequences to form stable double stranded structures, and in particular, oligonucleotides can cross-link to internal or terminal positions of DNA or RNA within a cell, which cross-link can prevent replication of the cell. Thus, the oligonucleotide can be used as a specific drug that binds to DNA or RNA of cancer cells, preventing the replication of cancer cells, and thus killing cancer cells. This method of treatment is called gene-targeted therapy because it is directed to specific gene mutations, not to all healthy or diseased cells.

In genetics, oligonucleotides are often used as probes for studying the structure and function of DNA and RNA. They can also be used for gene therapy, i.e. for the treatment of genetic diseases by modification of DNA or RNA sequences. In this process, the oligonucleotides may be designed to bind to abnormal gene sequences, thereby preventing the expression of the deleterious genes.

RNAi is a common gene expression control mechanism in organisms that can inhibit the expression of a specific gene by degrading the target RNA. During RNAi, double-stranded RNA (dsRNA) is a key effector molecule that can be cleaved by the intracellular RNaseIII enzyme into small fragments, which are called siRNAs (small interfering RNAs). The siRNA can bind to the target RNA, resulting in degradation of the target RNA, thereby inhibiting expression of a particular gene.

The 2' position is an important modification site during the synthesis of siRNA. At this position, the physicochemical properties and functions of the siRNA can be altered by the addition of chemical groups (e.g., methyl, ethyl, etc.). These modifications can increase the stability and specificity of the siRNA, allowing it to bind more efficiently to the target RNA, thereby more effectively inhibiting expression of a particular gene. Wherein: sugar-modified oligonucleotides are very important substances that alter the physicochemical properties and functions of siRNA, such as: the sugar-modified oligonucleotide can activate a subsequence of the 2' -deoxy-erythro-pentofuranosyl nucleoside of RNaseH, thereby promoting degradation of the target nucleic acid.

2' -O-propylated adenosines and ribosines were used as click targets for oligonucleotides cross-linked with aliphatic and aromatic azides. Crosslinking results in sugar modifications at the 2' -O linkage site. Inexpensive ribonucleosides are used as starting materials. The oligonucleotides are cross-linked at internal or terminal positions and the homodimer hybridizes to two complementary single strands to create a stable, linked DNA duplex. The cross-links formed in DNA can prevent cell replication, thus allowing cancer cells to die, a property that is widely used in cancer chemotherapy and genetics.

DMT-2' -O-propynyl-U-CE-phosphoramidite is an important pharmaceutical intermediate, but few documents at home and abroad report on its preparation method at present.

Disclosure of Invention

The invention aims to provide a preparation method of a medical intermediate, which has the following structural formula:

the preparation method of the medical intermediate comprises the following steps:

reacting 5'-O-DMT-2' -O-propynyl-uridine in a reaction solvent

Reacting with phosphoramidite reagent under the action of catalyst to obtain the medical intermediate named DMT-2' -O-propynyl-U-CE-phosphoramidite.

More specifically, the reaction solvent is selected from any one of dichloromethane, chloroform, acetonitrile and ethyl acetate.

More specifically, the catalyst is selected from one of tetrazole compounds and imidazole compounds.

Further specifically, the phosphoramidite reagent is selected from the group consisting of a compound of formula (I), a compound of formula (II)

Any one of the following.

Further specifically, the phosphoramidite reagent is used in an amount of about 3 equivalents, wherein "about" is used to adjust the value of the 10% change up and down.

Further specifically, the catalyst is used in an amount of about 2 equivalents, wherein "about" is used to adjust the value of the 10% change in the value up and down.

More specifically, the reaction time of the reaction is 12 to 14 hours.

More specifically, the reaction temperature of the reaction is 20-30 ℃.

More specifically, the reaction atmosphere of the reaction is an oxygen-free environment under the protection of inert gas.

The beneficial effects of the invention are as follows: the preparation method of DMT-2' -O-propynyl-U-CE-phosphoramidite designed by the application has the advantages of novel design, simple steps, no severe requirements of special reagents and reaction conditions, less side reactions in the reaction, and high product yield and purity.

Drawings

FIG. 1 is a schematic diagram of chemical structure of DMT-2' -O-propynyl-U-CE-phosphoramidite, a pharmaceutical intermediate in the present application;

FIG. 2 is a schematic chemical structure of 5'-O-DMT-2' -O-propynyl-uridine in the present application;

FIG. 3 is a schematic representation of the chemical structure of bis (diisopropylamino) (2-cyanoethoxy) phosphine in the present application;

FIG. 4 is a schematic representation of the chemical reaction scheme herein;

FIG. 5 is a schematic illustration of the chemical reaction mechanism in the present application;

FIG. 6 is a chart showing the nuclear magnetic resonance hydrogen spectrum of DMT-2' -O-propynyl-U-CE-phosphoramidite as a reaction product in example 1 of the present application;

FIG. 7 is a chart showing nuclear magnetic resonance phosphorus spectra of DMT-2' -O-propynyl-U-CE-phosphoramidite as a reaction product in example 1 of the present application;

FIG. 8 is a high performance liquid chromatogram of DMT-2' -O-propynyl-U-CE-phosphoramidite as a reaction product in example 1 of the present application.

Detailed Description

For the purposes of promoting an understanding of the principles and advantages of the invention, reference will now be made in detail to specific embodiments of the invention, some but not all of which are illustrated. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.

The use of the terms "a" and "an" and "the" and similar referents in the context of describing the elements (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the embodiments and does not pose a limitation on the scope of the claims unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential.

In this specification, "about" will mean plus or minus 10% of a particular term.

The invention provides a method for preparing a pharmaceutical intermediate DMT-2' -O-propynyl-U-CE-phosphoramidite,

the preparation method comprises the following steps: reacting 5'-O-DMT-2' -O-propynyl-uridine in a reaction solvent

And the DMT-2' -O-propynyl-U-CE-phosphoramidite is obtained by reacting with phosphoramidite reagent under the action of catalyst. The specific reaction equation is shown below:

the specific synthesis method comprises the following steps:

1) Adding a proper amount of reaction solvent into a reaction container, wherein the reaction container is protected by inert gas;

2) Slowly adding 5'-O-DMT-2' -O-propynyl-uridine, a catalyst and a phosphoramidite reagent into a reaction solvent at a low temperature of between-5 and 5 ℃ and fully stirring to uniformly mix the materials;

3) The temperature in the reaction vessel is regulated to 20-30 ℃ to enable the interior of the reaction vessel to fully react for 12-14 h, and the whole process in the reaction vessel is protected by inert gas;

4) The HPLC pilot reaction was complete.

In some embodiments, 5'-O-DMT-2' -O-propynyl-uridine is self-synthesized, and the temperature during the reaction is controlled by a 5L four port glass jacketed bottle and ethanol/water circulation bath apparatus; the shielding gas during the reaction is selected from any one of inert gases such as nitrogen and helium, and nitrogen is selected as the shielding gas in the following examples. The reaction solvent is selected from any one of dichloromethane, chloroform, acetonitrile and ethyl acetate, wherein in the following examples, dichloromethane is used as solvent, and is produced by Shanghai Lingfeng chemical reagent Co., ltd., commercial lot number: 20230422.

in some specific embodiments, the catalyst is selected from any one of tetrazole compounds and imidazole compounds, wherein the tetrazole compounds can be diisopropyl ammonium salt-tetrazole, and the imidazole compounds can be 4, 5-dicyanoimidazole. The catalyst and the phosphoramidite reagent need to be slowly added in the adding process, so that side reactions caused by excessive temperature of the solution due to heat release in the dissolving process are avoided. In the following examples, diisopropylammonium salt-tetrazole, commercially available from Norvekang Biotechnology Co., ltd., suzhou, was used as catalyst: 230728.

in some embodiments, the phosphoramidite reagent is selected from the group consisting of a compound of formula (I), a compound of formula (II)

Any one of the following. The compound bis (diisopropylamino) (2-cyanoethoxy) phosphine, of formula (I) was selected in the following examples as commercially available from Runyu New Material technologies Co., ltd: RV1361230412-RP172.

In some embodiments, the amount of bis (diisopropylamino) (2-cyanoethoxy) phosphine is about 3 equivalents and the amount of catalyst is about 2 equivalents, wherein "about" is used to adjust the value by a 10% change in the value. Bis (diisopropylamino) (2-cyanoethoxy) phosphine as a phosphoramidite reagent, as shown in figure 5,

diisopropylammonium salt tetrazole (compound 3) with lone pair of electrons nitrogen attacks the phosphorus of bis (diisopropylamino) (2-cyanoethoxy) phosphine (compound 2), followed by stripping off a part of diisopropylamine to form an intermediate, followed by 5'-O-DMT-2' -O-propynyl-uridine (compound 1) with 3 '-hydroxy oxygen, and stripping the tetrazole to give DMT-2' -O-propynyl-U-CE-phosphoramidite.

After the HPLC central control reaction is finished, the purified product is washed:

5) After the reaction is finished, adding a proper amount of water into a reaction container to perform catalytic washing for three times at 20-30 ℃;

6) At 20-30 ℃, a proper amount of saturated sodium chloride aqueous solution is used for catalytic washing in a reaction container for one time;

7) Transferring the organic phase, and concentrating under reduced pressure;

8) Separating and purifying by column chromatography, and concentrating under reduced pressure to obtain the target product.

In the experiment, the eluent is a mixed solution of dichloromethane and ethyl acetate during column chromatography separation and purification, and the ratio of the eluent is dichloromethane: ethyl acetate = 3: 1-2: 1.

example 1:

preparation of DMT-2' -O-propynyl-U-CE-phosphoramidite:

1) Adding 1L of dichloromethane into a reaction kettle, and introducing nitrogen into the reaction kettle for protection;

2) At the temperature of minus 2 ℃, 100.023g of the compound 5'-O-DMT-2' -O-propynyl-uridine and 0.171mol are added into a reaction kettle, and the mixture is stirred uniformly to be fully dissolved;

3) At the temperature of minus 2 ℃, 87.156g of compound diisopropyl ammonium tetrazole and 0.509mol are added into a reaction kettle, and the mixture is stirred uniformly to be fully dissolved;

4) 103.3831 g of the compound bis (diisopropylamino) (2-cyanoethoxy) phosphine and 0.343mol are added into a reaction kettle at the temperature of minus 2 ℃ and stirred uniformly to be fully dissolved;

5) Stirring for 30 minutes at-2 ℃;

6) Adjusting the temperature of the reaction kettle to 25 ℃, and protecting the whole process in the reaction container by inert gas;

7) The reaction was stirred at 25℃and the reaction time was 12h after completion of the HPLC pilot reaction.

Purification of DMT-2' -O-propynyl-U-CE-phosphoramidite:

8) Adding 1L of water into the reaction kettle, and washing the organic phase for three times;

9) Adding 1L of saturated sodium chloride aqueous solution into the reaction kettle, and washing the organic phase once;

10 Transferring the organic phase, concentrating under reduced pressure at 25deg.C, and pumping with water pump to vacuum degree of-0.1 MPa;

11 The organic phase is transferred, separated and purified by a column chromatography method, gradient elution is carried out, and 600mL of dichloromethane/ethyl acetate=3/1, 600mL of dichloromethane/ethyl acetate=2.5/1 and 500mL of dichloromethane/ethyl acetate=2/1 are sequentially selected as eluent.

12 The organic phase corresponding to the target product is collected, decompressed and concentrated at 25 ℃, and pumped by a water pump to vacuum degree of-0.1 MPa, 116.514 g,0.152mol, DMT-2' -O-propynyl-U-CE-phosphoramidite is finally obtained, and the yield is 88.89%.

The nuclear magnetic resonance hydrogen spectrum of the product DMT-2' -O-propynyl-U-CE-phosphoramidite is shown in FIG. 6, the nuclear magnetic resonance phosphorus spectrum is shown in FIG. 7, and the HPLC spectrum is shown in FIG. 8.

¹ The H NMR results are shown in fig. 6:

¹ H NMR(400MHz,CDCl3):d＝11.41(s,2H),7.75-7.80(m,2H),7.37-7.41(m,4H),7.31-7.33(m,4H),7.24-7.29(m,12H),6.88-6.92(m,9H),5.84-5.86(t,J＝4Hz,2H),5.29-5.34(m,2H),4.41-4.51(m,2H),4.31-4.37(m,6H),4.09-4.15(m,2H),3.76-3.82(m,2H),3.74(d,12H),3.05-3.67(m,7H),3.46-3.49(m,2H),3.25-3.32(m,2H),2.77-2.80(t,J＝4Hz,1H),2.60-2.63(t,J＝4Hz,1H),1.10-1.14(m,20H),0.97-0.99(m,6H)。

³¹ the P NMR results are shown in fig. 7:

³¹ P NMR(162MHz,CDCl3):d＝149.19,149.60. ³¹ p NMR purity of more than 97%

HPLC purity analysis was performed and the results are shown in fig. 8:

peak retention time No. 1 3.696min, peak area 0.467mau min, relative peak area 0.15%;

peak retention time No. 2 4.529min, peak area 0.867mau min, relative peak area 0.28%;

peak retention time No. 3 5.079min, peak area 0.576mau min, relative peak area 0.19%;

peak retention time No. 4 5.538min, peak area 3.882mau min, relative peak area 1.25%;

peak retention time No. 5 6.688min, peak area 2.382mau min, relative peak area 0.77%;

peak retention time No. 6 8.004min, peak area 301.535maχmin, relative peak area 97.22%;

peak retention time No. 7 11.313min, peak area 0.447mau min, relative peak area 0.14%;

peak No. 6 is DMT-2' -O-propynyl-U-CE-phosphoramidite with purity greater than 95% by HPLC.

Therefore, the DMT-2' -O-propynyl-U-CE-phosphoramidite prepared by the preparation method has high purity, few side reaction products and few impurities, and can be used for the next synthesis of medical compounds without complex further purification.

Example 2:

preparation of DMT-2' -O-propynyl-U-CE-phosphoramidite:

2) At 0 ℃, 100.257g of a compound of 5'-O-DMT-2' -O-propynyl-uridine and 0.171mol are added into a reaction kettle, and the mixture is stirred uniformly to be fully dissolved;

3) At 0 ℃, 89.178 g of compound diisopropylammonium tetrazole and 0.521mol of the compound are added into a reaction kettle, and the mixture is stirred uniformly to be fully dissolved;

4) 104.2915 g of compound bis (diisopropylamino) (2-cyanoethoxy) phosphine and 0.348 mol of the compound are added into a reaction kettle at the temperature of 0 ℃ and stirred uniformly to be fully dissolved;

5) Stirring for 30 minutes at 0 ℃;

Purification of DMT-2' -O-propynyl-U-CE-phosphoramidite:

12 The organic phase corresponding to the target product is collected, decompressed and concentrated at 25 ℃, and pumped by a water pump to vacuum degree of-0.1 MPa, thus obtaining 117.578 g,0.153mol, DMT-2' -O-propynyl-U-CE-phosphoramidite with the yield of 89.68 percent.

Example 3:

preparation of DMT-2' -O-propynyl-U-CE-phosphoramidite:

2) At the temperature of 5 ℃, 102.015g of a compound of 5'-O-DMT-2' -O-propynyl-uridine and 0.173mol are added into a reaction kettle, and the mixture is stirred uniformly to be fully dissolved;

3) At the temperature of 5 ℃, 87.680g of the compound diisopropylammonium tetrazole and 0.512mol of the compound are added into a reaction kettle, and the mixture is stirred uniformly to be fully dissolved;

4) Adding 107.951g of the compound bis (diisopropylamino) (2-cyanoethoxy) phosphine and 0.358mol into a reaction kettle at 5 ℃, and uniformly stirring to fully dissolve the compound bis (diisopropylamino) (2-cyanoethoxy) phosphine;

5) Stirring for 30 minutes at 0 ℃;

Purification of DMT-2' -O-propynyl-U-CE-phosphoramidite:

12 The organic phase corresponding to the target product is collected, decompressed and concentrated at 25 ℃, and pumped by a water pump to vacuum degree of-0.1 MPa, so as to finally obtain 115.592g,0.152mol, DMT-2' -O-propynyl-U-CE-phosphoramidite with the yield of 88.17 percent.

The embodiments of the present invention have been described in detail above, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.

Claims

1. A pharmaceutical intermediate, characterized in that the structural formula of the pharmaceutical intermediate is as follows:

2. a process for the preparation of a pharmaceutical intermediate according to claim 1, said process comprising:

reacting 5'-O-DMT-2' -O-propynyl-uridine with phosphoramidite reagent in a reaction solvent under the action of a catalyst to obtain the pharmaceutical intermediate.

3. The method for producing a pharmaceutical intermediate according to claim 2, wherein the reaction solvent is selected from any one of dichloromethane, chloroform, acetonitrile and ethyl acetate.

4. The method for producing a pharmaceutical intermediate according to claim 2, wherein the catalyst is selected from one of tetrazole-based compounds and imidazole-based compounds.

5. The process for preparing a pharmaceutical intermediate according to claim 2, wherein the phosphoramidite reagent is selected from the group consisting of a compound of formula (I), a compound of formula (II)

Any one of the following.

6. The process for preparing a pharmaceutical intermediate according to claim 2, wherein the phosphoramidite reagent is used in an amount of about 3 equivalents, wherein "about" is used to adjust the value of the 10% change up and down.

7. The process for preparing a pharmaceutical intermediate according to claim 2, wherein the catalyst is used in an amount of about 2 equivalents, wherein "about" is used to adjust the value of the 10% change up and down.

8. The process for producing a pharmaceutical intermediate according to claim 2, wherein the reaction time of the reaction is 12 to 14 hours.

9. The process for producing a pharmaceutical intermediate according to claim 2, wherein the reaction temperature of the reaction is 20 to 30 ℃.

10. The method for producing a pharmaceutical intermediate according to claim 2, wherein the reaction atmosphere of the reaction is an oxygen-free atmosphere under the protection of inert gas.